Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received the first dose of RabAvert on day 0 and second dose on day 4; Case reference number US-BN-2024-002346 is a spontaneous case initially received from a pharmacist via Med Communications (reference number USBAV24-1967) on 14-Aug-2024 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, reported as day zero, the patient received the first dose of RabAvert vaccine (batch number: unknown), at an unknown dose, route or site of administration, for pre-exposure. On an unspecified date, reported as day four, the patient received the second dose of RabAvert vaccine (batch number: unknown), at an unknown dose, route or site of administration (explicitly coded ' inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A male patient of unspecified age received the second dose of RabAvert vaccine for pre-exposure, reported as on the day 4, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age received the second dose of RabAvert vaccine for pre-exposure, reported as on the day 4, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious. USBAV24-1967:
Comments: None